Bristol Myers Squibb (BMY) announced Wednesday that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.
from RTT - Biotech https://ift.tt/3d8qFF9
via IFTTT
No comments:
Post a Comment